PROGNOSTIC SIGNIFICANCE OF STRUMAL CALLA EXPRESSION IN PRIMARY BREAST CARCINOMA IN RELATION TO PATHOLOGICAL RSPONCE AFTER NEOADJUVANT CHEMOTHERAPY

Background: In this study we aimed to assess the IHC expression of stromal CALLA in invasive breast carcinomas as prognostic factor and correlate its relationship with six clinico-pathological parametrs by assessing the pathological response to neoadjuvant chemotherapy Method: Study design is cross-sectional, it conducted on 50 females with breast invasive ductal carcinoma, FFPE tissue blocks collected from the archive of laboratory of Al-Sader medical city - Al Najaf governorate/ Iraq, during the period from September 2023 to September 2024. CALLA immunohistochemistry expression detected by labeled polymers and enhanced polymer system (Dako En-Vision™ Flex) Dako-protocol. it was correlated with age of patients, tumor grade, hormonal expression, her-2/neo expression, Ki-67 expression and molecular profile.Result: Stromal CALLA immunohistochemistry was expressed in 48%. There is statistically significant positive correlations between stromal expression and response to neoadjuvant chemotherapy (P = 0.011), most cases with positive CALLA expression either nonresponding to NAC or achieved partial response while most of CALLA negative cases achieved complete pathological response the same for her-2 positive cases, though statistically non-significant but most CALLA expressed cases were Grade III, her-2 enriched and triple negative molecular profile most of them had partial pathological response (not complete) Conclusions: Stromal CALLA had been expressed in 48% of invasive ductal carcinoma and there is positive correlation between stromal CALLA expressions and higher tumor grades, her-2 expression and triple negative profile suggesting the effects of stromal CALLA expression on aggressive behavior of breast ductal carcinoma with decreasing a chance of complete pathological response after neoadjuvant chemotherapy Key words: CALLA immunohistochemistry, CD-10, breast carcinoma, prognostic factor, neoadjuvant chemotherapy, molecular profile.